Hemophilia Treatment Market Trends Analysis
Hemophilia a rare disorder is estimated to affect about 1 of every 5,000 male births. According to the Hemophilia treatment centres (for the time period 2012-2018), about 20,000 as many as 33,000 males in the United States are living with Hemophilia. It is observed that Hemophilia affects people hailing from all races and ethnicities. Based on the level of clotting factor in the blood, Hemophilia can be divide into three types namely mild, moderate, or severe, as per recent studies it is noticed the majority of Hemophilia patients have a severe form.
As of now, there is no cure available in the Hemophilia market. However, to provide effective therapeutics options, some of the key pharmaceutical companies like BioMarin Pharmaceutical, Novo Nordisk, Pfizer, Sangamo Therapeutics, Sanofi, Alnylam Pharmaceuticals, Catalyst Biosciences, Roche, Spark Therapeutics, Sigilon Therapeutics, Takeda, and others are developing novel treatment approaches to treat Hemophilia.
For more details, visit: Hemophilia Treatment Market Trends Analysis